XNAS:CYTK Cytokinetics Inc Insider Activity 4 Filing - 9/4/2012

Effective Date 9/4/2012

XNAS:CYTK (Cytokinetics Inc): Fair Value Estimate
Premium
XNAS:CYTK (Cytokinetics Inc): Consider Buying
Premium
XNAS:CYTK (Cytokinetics Inc): Consider Selling
Premium
XNAS:CYTK (Cytokinetics Inc): Fair Value Uncertainty
Premium
XNAS:CYTK (Cytokinetics Inc): Economic Moat
Premium
XNAS:CYTK (Cytokinetics Inc): Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Malik Fady Ibraham
  2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [CYTK]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP Research & Early Dev
(Last)
(First)
(Middle)
280 EAST GRAND AVENUE
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2012
(Street)

SOUTH SAN FRANCISCO, CA 94080
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/04/2012   M   87,500 A (1) 121,132 D  
Common Stock 09/04/2012   F(2)   32,052 D $0.7598 89,080 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 09/04/2012   M     87,500   (3)   (3) Common Stock 87,500 $ 0 87,500 D  
Incentive Stock Option (right to buy) $1.05             04/05/2012(4) 03/05/2022 Common Stock 136,434   136,434 D  
Incentive Stock Option (right to buy) $1.57             03/31/2011(5) 02/28/2021 Common Stock 71,298   71,298 D  
Incentive Stock Option (right to buy) $1.85             03/26/2009(6) 02/26/2019 Common Stock 31,669   31,669 D  
Incentive Stock Option (right to buy) $3.08             03/24/2010(7) 02/24/2020 Common Stock 44,954   44,954 D  
Incentive Stock Option (right to buy) $3.37             03/29/2008(8) 02/28/2018 Common Stock 10,395   10,395 D  
Incentive Stock Option (right to buy) $6.5             03/01/2004(9) 03/04/2014 Common Stock 12,500   12,500 D  
Incentive Stock Option (right to buy) $6.81             04/01/2007(10) 03/14/2017 Common Stock 17,722   17,722 D  
Incentive Stock Option (right to buy) $7.04             04/01/2006(11) 03/15/2016 Common Stock 35,000   35,000 D  
Incentive Stock Option (right to buy) $7.1             04/01/2005(12) 03/23/2015 Common Stock 9,000   9,000 D  
Non-Qualified Stock Option (right to buy) $1.05             04/05/2012(4) 03/05/2022 Common Stock 38,566   38,566 D  
Non-Qualified Stock Option (right to buy) $1.57             03/31/2011(5) 02/28/2021 Common Stock 3,702   3,702 D  
Non-Qualified Stock Option (right to buy) $1.85             03/26/2009(6) 02/26/2019 Common Stock 8,331   8,331 D  
Non-Qualified Stock Option (right to buy) $3.08             03/24/2010(7) 02/24/2020 Common Stock 5,046   5,046 D  
Non-Qualified Stock Option (right to buy) $3.37             03/29/2008(8) 02/28/2018 Common Stock 8,415   8,415 D  
Non-Qualified Stock Option (right to buy) $6.81             04/01/2007(10) 03/14/2017 Common Stock 2,078   2,078 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Malik Fady Ibraham
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
      SVP Research & Early Dev  

Signatures

 Fady Malik, M.D., Ph.D.   09/05/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each restricted stock unit represents a contingent right to receive one share of CYTK common stock at a purchase price of $0.001 per share which is the current par value of the common stock.
(2) Shares withheld by Issuer to cover taxes associated with settlement of Restricted Stock Units
(3) The restricted stock units vest in two equal annual installments. Vested shares will be delivered to the reporting person on 9/4/2012 and 9/3/2013.
(4) When the ISO and NQ dated 03/05/2012 are combined for a total grant of 175,000 shares, the option shall vest and become exercisable as to 3,645 shares on 04/05/2012 and the balance of 171,355 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/05/2016.
(5) When the ISO and NQ dated 02/28/2011 are combined for a total grant of 75,000 shares, the option shall vest and become exercisable as to 1,562 shares on 03/31/2011 and the balance of 73,438 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/28/2015.
(6) When the ISO and NQ dated 02/26/2009 are combined for a total grant of 40,000 shares, the option shall vest and become exercisable as to 833 shares on 03/26/09 and the balance of 39,167 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/26/13.
(7) When the ISO and NQ dated 02/24/2010 are combined for a total grant of 50,000 shares, the option shall vest and become exercisable as to 1,041 shares on 03/24/2010 and the balance of 48,959 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/2014.
(8) When the ISO and NQ dated 02/29/2008 are combined for a total grant of 18,810 shares, the option shall vest and become exercisable as to 391 shares on 03/29/08 and the balance of 18,419 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/29/12.
(9) This option is immediately exercisable upon grant and shall vest as to 260 shares on 04/01/04 and the balance of 12,240 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/08.
(10) When the ISO and NQ dated 03/14/2007 are combined for a total grant of 19,800 shares, the option shall vest and become exercisable as to 412 shares on 04/01/07 and the balance of 19,388 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/11.
(11) This option shall vest and become exercisable as to 729 shares on 04/01/06 and the balance of 34,271 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/10.
(12) This option shall vest and become exercisable as to 187 shares on 04/01/05 and the balance of 8,813 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/09.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:CYTK Cytokinetics Inc Insider Activity 4 Filling

Cytokinetics Inc XNAS:CYTK Stock - Get Insider Activity SEC Filing of Cytokinetics Inc XNAS:CYTK stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XNAS:CYTK Cytokinetics Inc Insider Activity 4 Filing - 9/4/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:CYTK Cytokinetics Inc Insider Activity 4 Filing - 9/4/2012  |  Next: XNAS:CYTK Cytokinetics Inc Insider Activity 4 Filing - 9/4/2012